Medical device manufacturer Tentech (CEO Han Dong-ok) announced on the 21st that it has signed a supply contract worth KRW 60 billion with Feizer, a Chinese medical aesthetics distribution company.

Under this agreement, Tentech will supply 1,500 units of the '10THERMA' device over the next three years. Following its successful contract with China's Paragon in 2023, Tentech has further strengthened its position in the Chinese market by securing this additional deal with Feizer.

Feizer is a rapidly growing company specializing in the distribution of medical aesthetic products, primarily in western China. Over the past decade, it has established a direct sales network and continues to expand its business nationwide. Beyond simple distribution, Feizer focuses on physician education, hospital management consulting, and ongoing engagement with end consumers, helping maximize hospital profitability. This strategy enables the company to maintain long-term competitiveness in the market.

The contract was finalized during the 2025 KIMES (Korea International Medical & Hospital Equipment Show), where Tentech showcased its cutting-edge medical aesthetic devices at booth A510. Among its product lineup, the '10THERMA' device stood out as a lifting solution utilizing proprietary 6.78MHz RF energy, clinically proven to improve skin elasticity and reduce wrinkles. Equipped with Smart Temperature Control (STC) technology and impedance-matching features, 10THERMA enhances procedural safety while minimizing discomfort. Additionally, the device offers a range of tip sizes, making it suitable for both facial and body lifting applications, which has led to high satisfaction among medical professionals.

A Tentech representative stated, "This partnership with Feizer is expected to create significant synergy in the Chinese medical aesthetics market. The combination of 10THERMA advanced technology and Feizer’s strong distribution network will enable us to rapidly increase market share."

Tentech CEO Han Dong-ok added, "Through our collaboration with Feizer, we plan to execute a more aggressive marketing and distribution strategy in China. This contract will serve as a stepping stone for further strengthening our competitiveness in the global medical aesthetics market."